Presentation (CTI)

OBJECTIVES: Post-approval, monitoring adverse drug reactions (ADRs) is vital. Analyzing in-house ADR data enables swift safety assessment, providing valuable feedback to inform clinical care.
METHODS: This retrospective analysis collected and examined ADR cases reported in our hospital during the years 2021-2022. Analytical parameters included the number of reports, gender distribution, sources of occurrence, reporting sources, types ofADRs, post-ADR management, follow-up procedures, ADR correlations, ATC code classification of reported drugs, and classification of ADRs.
RESULTS: In 2021-2022, 804 cases of adverse drug reactions (ADRs) were reported through our hospital's internal system. Analyzing 156 cases related to our medications revealed physicians as the primary reporters (84.6%), mainly in outpatient settings(75.6%). Type B reactions were common (78.2%), with discontinuation as the primary intervention (35.3%), and follow-up focusing on symptom relief (98.7%). Drugs were classified by Anatomical Therapeutic Chemical (ATC) code, with Alimentary Tract andMetabolism prevailing (34.0%). Dermatologic Effects were the primary category for reported adverse reactions(51.9%). In ranking drugs associated with ADRs, iobitridol topped the list, followed by iohexol, metoclopramide, andmosapride. These dataoffer comprehensive insights into ADRs, contributing to improved medication safety.
CONCLUSIONS: Through active voluntary reporting of adverse drug reactions (ADRs), we comprehensively understand rare occurrences and deepen healthcare professionals' awareness. This voluntary reporting mechanism aids timely risk identification, enhancing overall healthcare safety.